Grading dermatologic adverse events of cancer treatments: The Common Terminology Criteria for Adverse Events Version 4.0

被引：337

作者：

Chen, Alice P. ^{[2
]}

Setser, Ann ^{[3
]}

Anadkat, Milan J. ^{[4
]}

Cotliar, Jonathan ^{[5
]}

Olsen, Elise A. ^{[6
,7
]}

Garden, Benjamin C. ^{[1
]}

Lacouture, Mario E. ^{[1
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Dept Med, Dermatol Serv, New York, NY 10022 USA

[2] NCI, Med Oncol Clin Res Unit, Ctr Canc Res, NIH, Bethesda, MD 20892 USA

[3] NCI, Invest Drug Branch, NIH, Canc Therapy Evaluat Program, Rockville, MD USA

[4] Washington Univ, Sch Med, Div Dermatol, St Louis, MO 63110 USA

[5] Northwestern Univ, Feinberg Sch Med, Dept Dermatol, Chicago, IL 60611 USA

[6] Duke Univ, Med Ctr, Dept Med, Div Dermatol, Durham, NC 27710 USA

[7] Duke Univ, Med Ctr, Dept Med, Div Oncol, Durham, NC 27710 USA

来源：

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2012年 / 67卷 / 05期

基金：

美国国家卫生研究院;

关键词：

adverse events; cancer treatment; Common Terminology Criteria for Adverse Events; drug reactions; grading system; side effects; HAND-FOOT SYNDROME; INDUCED SKIN RASH; CLINICAL-SIGNIFICANCE; CUTANEOUS REACTIONS; TOXICITY; MANAGEMENT; CETUXIMAB; CHEMOTHERAPY; PATHOGENESIS; INHIBITORS;

D O I：

10.1016/j.jaad.2012.02.010

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Dermatologic adverse events to cancer therapies have become more prevalent and may to lead to dose modifications or discontinuation of life-saving or prolonging treatments. This has resulted in a new collaboration between oncologists and dermatologists, which requires accurate cataloging and grading of side effects. The Common Terminology Criteria for Adverse Events Version 4.0 is a descriptive terminology and grading system that can be used for uniform reporting of adverse events. A proper understanding of this standardized classification system is essential for dermatologists to properly communicate with all physicians caring for patients with cancer. (J Am Acad Dermatol 2012;67:1025-39.)

引用

页码：1025 / 1039

页数：15

共 34 条

[1]

Agha R, 2007, ONCOLOGY-NY, V21, P1462

[2]

[Anonymous], ICH HARM TRIP GUID P

[3] The emergence of supportive oncodermatology: The study of dermatologic adverse events to cancer therapies [J].

Balagula, Yevgeniy ;

Rosen, Steven T. ;

Lacouture, Mario E. .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2011, 65 (03) :624-635

[4] Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck [J].

Bernier, J. ;

Bonner, J. ;

Vermorken, J. B. ;

Bensadoun, R-J. ;

Dummer, R. ;

Giralt, J. ;

Kornek, G. ;

Hartley, A. ;

Mesia, R. ;

Robert, C. ;

Segaert, S. ;

Ang, K. K. .

ANNALS OF ONCOLOGY, 2008, 19 (01) :142-149

[5] Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer [J].

Buckner, Jan C. ;

Forouzesh, Bahram ;

Erlichman, Charles ;

Hidalgo, Manuel ;

Boni, Joseph P. ;

Dukart, Gary ;

Berkenblit, Anna ;

Rowinsky, Eric K. .

INVESTIGATIONAL NEW DRUGS, 2010, 28 (03) :334-342

[6]

Chalid A, 2008, FITZPATRICKS DERMATO

[7] Dermatologic Infections in Cancer Patients Treated With Epidermal Growth Factor Receptor Inhibitor Therapy [J].

Eilers, R. E., Jr. ;

Gandhi, M. ;

Patel, J. D. ;

Mulcahy, M. F. ;

Agulnik, M. ;

Hensing, T. ;

Lacouture, Mario E. .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2010, 102 (01) :47-53

[8] Sorafenib in advanced clear-cell renal-cell carcinoma [J].

Escudier, Bernard ;

Eisen, Tim ;

Stadler, Walter M. ;

Szczylik, Cezary ;

Oudard, Stephane ;

Siebels, Michael ;

Negrier, Sylvie ;

Chevreau, Christine ;

Solska, Ewa ;

Desai, Apurva A. ;

Rolland, Frederic ;

Demkow, Tomasz ;

Hutson, Thomas E. ;

Gore, Martin ;

Freeman, Scott ;

Schwartz, Brian ;

Shan, Minghua ;

Simantov, Ronit ;

Bukowski, Ronald M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (02) :125-134

[9]

Fleta-Asin Beatriz, 2009, Dermatol Online J, V15, P7

[10] Severe pustular eruption associated with imatinib and voriconazole in a patient with chronic myeloid leukemia [J].

Gambillara, E ;

Laffitte, E ;

Widmer, N ;

Decosterd, LA ;

Duchosal, MA ;

Kovacsovics, T ;

Panizzon, RG .

DERMATOLOGY, 2005, 211 (04) :363-365

← 1 2 3 4 →